Literature DB >> 3260450

HLA-B27: an important genetic risk factor for lone aortic regurgitation and severe conduction system abnormalities.

L Bergfeldt1, P Insulander, D Lindblom, E Möller, O Edhag.   

Abstract

PURPOSE: HLA-B27, an immunogenetic marker that is present in 8 percent of the white population around the world, has been found to be an important risk factor for the development of a group of rheumatic disorders, the seronegative spondyloarthropathies. Our objective was to assess the possible role of HLA-B27 and the associated inflammatory disease process in the development of lone aortic regurgitation. PATIENTS AND METHODS: A group of 91 patients with lone aortic regurgitation were studied by HLA typing and clinical and roentgenologic examination.
RESULTS: The HLA-B27-associated inflammatory disease process was found to be the probable underlying cause in 15 to 20 percent of patients with lone aortic regurgitation of different degrees of severity. Furthermore, HLA-B27 was found in 88 percent of the male patients with the combination of aortic regurgitation and severe conduction system abnormalities.
CONCLUSION: We suggest that this cardiac syndrome should be regarded as an HLA-B27-associated syndrome, sometimes part of ankylosing spondylitis or Reiter's disease, but just as often presenting without obvious rheumatic disease. The marker is thus an important and widely distributed risk factor not only for the development of rheumatic disease but also for acquired aortic regurgitation and sever conduction system abnormalities.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260450     DOI: 10.1016/0002-9343(88)90497-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions.

Authors:  Jürgen Braun; Klaus Krüger; Bernhard Manger; Matthias Schneider; Christof Specker; Hans Joachim Trappe
Journal:  Dtsch Arztebl Int       Date:  2017-03-24       Impact factor: 5.594

2.  Aortic valve insufficiency in patients with chronic rheumatic diseases.

Authors:  Paavo Uusimaa; Maija-Liisa Krogerus; Juhani Airaksinen; Markku Linnaluoto; Osmo Tervonen; Markku Hakala
Journal:  Clin Rheumatol       Date:  2005-10-11       Impact factor: 2.980

3.  Platelet aggregating activity in serum from patients with HLA-B27 associated rheumatic and cardiac disorders: a possible link to the proliferative vascular changes.

Authors:  L Bergfeldt; O Edhag; G Holm; R Norberg
Journal:  Br Heart J       Date:  1991-04

Review 4.  Axial spondyloarthritis: the heart of the matter.

Authors:  Lianne S Gensler
Journal:  Clin Rheumatol       Date:  2015-05-10       Impact factor: 2.980

5.  Aortic insufficiency in a patient with reactive arthritis: case report and review of the literature.

Authors:  Lorrel E Brown; Paul Forfia; John A Flynn
Journal:  HSS J       Date:  2011-01-14

Review 6.  'MHC-I-opathy'-unified concept for spondyloarthritis and Behçet disease.

Authors:  Dennis McGonagle; Sibel Zehra Aydin; Ahmet Gül; Alfred Mahr; Haner Direskeneli
Journal:  Nat Rev Rheumatol       Date:  2015-11-03       Impact factor: 20.543

7.  Cardiac Manifestations of Seronegative Spondyloarthropathy in a Human Leukocyte Antigen B27-Positive African American Woman: A Case Report With Literature Review.

Authors:  Olisaemeka Achike; Adeyemi Taiwo; Rajasekhar Nekkanti; Constantin Bogdan Marcu
Journal:  CASE (Phila)       Date:  2019-06-12

8.  Lifetime Risks of Valvular Heart Disease and Pacemaker Use in Patients With Ankylosing Spondylitis.

Authors:  Michael M Ward
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

9.  Aortic root diameter is associated with HLA-B27: identifying the patient with ankylosing spondylitis at risk for aortic valve regurgitation.

Authors:  M Baniaamam; S C Heslinga; T C Konings; M L Handoko; O Kamp; V P van Halm; I E van der Horst-Bruinsma; M T Nurmohamed
Journal:  Rheumatol Int       Date:  2021-11-02       Impact factor: 2.631

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.